These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26152654)

  • 21. Language production in Parkinson's disease: acoustic and linguistic considerations.
    Illes J; Metter EJ; Hanson WR; Iritani S
    Brain Lang; 1988 Jan; 33(1):146-60. PubMed ID: 3342316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prominence marking in parkinsonian speech and its correlation with motor performance and cognitive abilities.
    Thies T; Mücke D; Lowit A; Kalbe E; Steffen J; Barbe MT
    Neuropsychologia; 2020 Feb; 137():107306. PubMed ID: 31857118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
    De Letter M; Santens P; Estercam I; Van Maele G; De Bodt M; Boon P; Van Borsel J
    Clin Linguist Phon; 2007 Oct; 21(10):783-91. PubMed ID: 17882694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing disordered speech and voice in Parkinson's disease: a telerehabilitation application.
    Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
    Int J Lang Commun Disord; 2010; 45(6):630-44. PubMed ID: 20102257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Speech-related fatigue and fatigability in Parkinson's disease.
    Makashay MJ; Cannard KR; Solomon NP
    Clin Linguist Phon; 2015 Jan; 29(1):27-45. PubMed ID: 25152085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intelligibility of dysarthric speech: perceptions of speakers and listeners.
    Walshe M; Miller N; Leahy M; Murray A
    Int J Lang Commun Disord; 2008; 43(6):633-48. PubMed ID: 18608608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A serious game for speech training in dysarthric speakers with Parkinson's disease: Exploring therapeutic efficacy and patient satisfaction.
    Ganzeboom M; Bakker M; Beijer L; Strik H; Rietveld T
    Int J Lang Commun Disord; 2022 Jul; 57(4):808-821. PubMed ID: 35338751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioural intervention effects in dysarthria following stroke: communication effectiveness, intelligibility and dysarthria impact.
    Mackenzie C; Lowit A
    Int J Lang Commun Disord; 2007; 42(2):131-53. PubMed ID: 17365091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Speech and Communication Changes Reported by People with Parkinson's Disease.
    Schalling E; Johansson K; Hartelius L
    Folia Phoniatr Logop; 2017; 69(3):131-141. PubMed ID: 29346787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stop consonant production in isolated and repeated syllables in Parkinson's disease.
    Connor NP; Ludlow CL; Schulz GM
    Neuropsychologia; 1989; 27(6):829-38. PubMed ID: 2755591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining the relationship between speech intensity and self-rated communicative effectiveness in individuals with Parkinson's disease and hypophonia.
    Dykstra AD; Adams SG; Jog M
    J Commun Disord; 2015; 56():103-12. PubMed ID: 26188950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Markerless Analysis of Articulatory Movements in Patients With Parkinson's Disease.
    Bandini A; Orlandi S; Giovannelli F; Felici A; Cincotta M; Clemente D; Vanni P; Zaccara G; Manfredi C
    J Voice; 2016 Nov; 30(6):766.e1-766.e11. PubMed ID: 26620259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Speech Prosody Across Stimulus Types for Individuals with Parkinson's Disease.
    K-Y Ma J; Schneider CB; Hoffmann R; Storch A
    J Parkinsons Dis; 2015; 5(2):291-9. PubMed ID: 25697957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting Intelligibility Gains in Dysarthria Through Automated Speech Feature Analysis.
    Fletcher AR; Wisler AA; McAuliffe MJ; Lansford KL; Liss JM
    J Speech Lang Hear Res; 2017 Nov; 60(11):3058-3068. PubMed ID: 29075755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Speech and pause characteristics associated with voluntary rate reduction in Parkinson's disease and Multiple Sclerosis.
    Tjaden K; Wilding G
    J Commun Disord; 2011; 44(6):655-65. PubMed ID: 21767851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ataxic dysarthria: treatment sequences based on intelligibility and prosodic considerations.
    Yorkston KM; Beukelman DR
    J Speech Hear Disord; 1981 Nov; 46(4):398-404. PubMed ID: 7300267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of increased vocal intensity on interarticulator timing in speakers with Parkinson’s disease: a preliminary analysis.
    Richardson K; Sussman JE; Stathopoulos ET
    J Commun Disord; 2014; 52():44-64. PubMed ID: 25459460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparing an E-learning-based Speech Therapy (EST) efficacy study: Identifying suitable outcome measures to detect within-subject changes of speech intelligibility in dysarthric speakers.
    Beijer LJ; Rietveld AC; Ruiter MB; Geurts AC
    Clin Linguist Phon; 2014 Dec; 28(12):927-50. PubMed ID: 25025268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The interpretation of dysprosody in patients with Parkinson's disease.
    Caekebeke JF; Jennekens-Schinkel A; van der Linden ME; Buruma OJ; Roos RA
    J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):145-8. PubMed ID: 2019840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of SPEAK OUT! & LOUD Crowd on Functional Speech Measures in Parkinson's Disease.
    Sullivan L; Martin E; Allison KM
    Am J Speech Lang Pathol; 2024 Jul; 33(4):1930-1951. PubMed ID: 38838243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.